School of Medicine
Showing 21-30 of 43 Results
-
Uri Ladabaum
Professor of Medicine (Gastroenterology and Hepatology)
Current Research and Scholarly InterestsGastrointestinal cancer prevention and risk management. Risk stratification. Cost-effectiveness analysis. Health services research.
-
Marvin Langston
Assistant Professor of Epidemiology and Population Health
BioDr. Marvin Langston is an Assistant Professor of Epidemiology and Population Health. He is a member of the Stanford Cancer Institute and Urologic Cancer Epidemiology Lab. He is an epidemiologist by training who focuses on the fields of benign prostate and pelvic conditions and urological cancers including prostate and kidney cancers.
Prior to Stanford, he served as a Research Scientist in the Division of Research at Kaiser Permanente Northern California. Dr. Langston received his PhD in Epidemiology from the University of Arizona’s College of Public Health followed by postdoctoral training in Cancer Prevention and Control at Washington University in Saint Louis School of Medicine.
His program of research intends to characterize and measure infectious agents, environmental toxicants, and lifestyle factors; to evaluate the role of these factors in urological cancer etiology and outcomes; and to identify populations at high risk of exposure to these factors. So far he has focused this research to address the following questions: 1) What role do sexually transmitted infections and other systemic infections have in prostate damage and ensuing prostate cancer risk? 2) How can we appropriately model and define early life risk factors for urological cancers? 3) Can we harmonize molecular and clinical aspects of urological condition diagnoses to produce well characterized outcomes for biomarker discovery and etiological investigation? He has primarily addressed these questions using a variety of molecular and clinical epidemiology approaches while developing expertise in the cross-cutting theme of cancer health disparities with particular interests in the cancer care experiences of sexual and gender minorities and racial/ethnic minorities.
Dr. Langston has been studying the impact of exogenous factors on prostate specific antigen (PSA) concentration in young men as a marker of prostate damage and inflammation for over a decade. As early life PSA has been found predictive of future prostate cancer mortality, he has now setout to optimize risk-stratified screening for prostate cancer. This promising approach uses men’s baseline PSA values to inform their risk of future aggressive and/or fatal prostate cancer and determine their frequency of further screening. Under this approach, men with high baseline age-specific total PSA levels receive more frequent screening and men with lower levels receive less frequent screening. Dr. Langston was awarded an R01 from NCI to evaluate this approach using historically collected biospecimen. His funded research trajectory to this point also includes four training awards (2-NCI and 2-NIDDK) and several internal grants. Dr. Langston was selected in the inaugural class of the White House Cancer Moonshot Scholars for his work. -
Jennifer Lee
Professor of Medicine (Endocrinology) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsI am a clinical scientist (PhD epidemiology), endocrinologist, and CMO at VAPA Cooperative Studies Program Coordinating Center. My group does pattern and prediction mapping along the life-course of interventions/outcomes and how healthcare system can positively impact health longitudinally. We use novel molecular epi, 'big' data like EHRs using multiple designs/methods/technologies. These interests cut across multiple complex chronic diseases and lifespan.
https://med.stanford.edu/jleelab.html -
Eleni Linos, MD, MPH, DrPH
Associate Dean for Research, Ben Davenport and Lucy Zhang Professor of Medicine, Professor, of Medicine (Center for Digital Health) and, by courtesy, of Epidemiology and Population Health
BioEleni Linos MD, MPH, DrPH, is the Director of the Stanford Center for Digital Health. She is a Professor of Dermatology and Epidemiology at Stanford University. Dr. Linos also serves as an Associate Dean for Research, leading the KL2 Research Training Program.
Dr. Linos' research focuses on the use of technology in health, dermatology, public health, cancer prevention and the care of older adults. She is dually trained in epidemiology and dermatology and is the principal investigator of several NIH funded studies aimed at improving the lives of patients. She received her medical degree from Cambridge and Oxford universities in the UK, received a masters and doctoral degree from the Harvard School of Public Health and completed her residency at Stanford. -
Karl Lorenz
Professor of Medicine (Primary Care and Population Health)
BioDr. Karl Lorenz, MD MSHS is a general internal medicine and palliative care physician, and Section chief of the VA Palo Alto-Stanford Palliative Care Program. Formerly at the VA Greater Los Angeles, Dr. Lorenz directed palliative care research at the VA Center for Innovation to Implementation and served on the faculty at the UCLA School of Medicine. Dr. Lorenz is a member of the VA’s national Hospice and Palliative Care Program (HPC) leadership team, director of the operational palliative care Quality Improvement Resource Center (QuIRC), and adjunct facility staff member at RAND. Dr. Lorenz’s work and leadership has been influential to the field of palliative care research. Under Dr. Lorenz’s leadership, since 2009 the Quality Improvement Resource Center (QuIRC) has served as one of three national leadership Centers responsible for strategic and operational support of the VA’s national hospice and palliative care programs. QuIRC develops and implements provider facing electronic tools for the VA’s national electronic medical record to improve the quality of palliative care. In that role, Dr. Lorenz participates with the national leadership team in strategic planning, policy development, and providing resources to support operational efforts. Dr. Lorenz has contributed to the field of global palliative care, serving the World Health Organization in its development of Palliative Care for Older People and leading methods for Palliative Care Essential Medications.
-
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsWe conduct clinical trials and epidemiological, translational, and real-world studies of liver cancer, fatty liver (NASH, NAFLD), viral hepatitis B and C, liver cirrhosis, and liver transplant. We focus on risk identification for disease prevention and treatment for improvement of survival. We focus on sex, racial/ethnic, and socioeconomic disparities. We specialize in clinical trials, large international real-world consortium registry data, and large public/semi-public databases.
-
Doug Owens
Henry J. Kaiser, Jr. Professor, Senior Fellow at the Freeman Spogli Institute for International Studies and Professor, by courtesy, of Management Science and Engineering
Current Research and Scholarly InterestsMy research uses decision modeling, cost-effectiveness analysis, and meta-analysis to evaluate clinical and health policy problems. Much of my work involves development of national guidelines for prevention and treatment.
-
VJ Periyakoil, Professor of Medicine
Professor of Medicine (Primary Care and Population Health)
Current Research and Scholarly InterestsMy lab is focused on longevity and healthy aging, multi-cultural palliative care and geriatrics research.
-
Sylvia K. Plevritis, PhD
William M. Hume Professor in the School of Medicine, Professor of Biomedical Data Science and of Radiology
Current Research and Scholarly InterestsMy research program focuses on computational modeling of cancer biology and cancer outcomes. My laboratory develops stochastic models of the natural history of cancer based on clinical research data. We estimate population-level outcomes under differing screening and treatment interventions. We also analyze genomic and proteomic cancer data in order to identify molecular networks that are perturbed in cancer initiation and progression and relate these perturbations to patient outcomes.
